Feasibility and outcome of HCV treatment in a Canadian federal prison population

被引:43
作者
Farley, J
Vasdev, S
Fischer, B
Haydon, E
Rehm, J
Farley, TA
机构
[1] Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] John Farley Inc, Vancouver, BC, Canada
[4] Univ Ottawa, Ottawa, ON K1N 6N5, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Res Inst Addict, Zurich, Switzerland
关键词
D O I
10.2105/AJPH.2004.056150
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
We assessed feasibility and outcome of hepatitis C virus (HCV) treatment in male correctional inmates in British Columbia, Canada. We reviewed the medical charts of 114 treated inmates; 80 had complete data for treatment outcome. Approximately 4 of 5 inmates completed treatment (78.8%); 66.3% achieved sustained virological response. Those who completed treatment, those with injection drug use as a risk factor, and those with genotypes 2 and 3 were significantly more likely to achieve sustained virological response. HCV treatment in correctional inmates is feasible and effective.
引用
收藏
页码:1737 / 1739
页数:3
相关论文
共 20 条
  • [1] Treatment of chronic hepatitis C in a state correctional facility
    Allen, SA
    Spaulding, AC
    Osei, AM
    Taylor, LE
    Cabral, AM
    Rich, JD
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (03) : 187 - 190
  • [2] [Anonymous], 2004, Can J Public Health, V95 Suppl 1, pS9
  • [3] Prior opiate injection and incarceration history predict injection drug use among inmates
    Calzavara, LM
    Burchell, AN
    Schlossberg, J
    Myers, T
    Escobar, M
    Wallace, E
    Major, C
    Strike', C
    Millson, M
    [J]. ADDICTION, 2003, 98 (09) : 1257 - 1265
  • [4] *CAN HIV AIDS LEG, 2002, ACT HIV AIDS PRIS LI
  • [5] *CORR SERV CAN, 2003, INF DIS PREV CONTR
  • [6] De Prithwish, 2004, Can J Infect Dis Med Microbiol, V15, P221
  • [7] Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
    Edlin, BR
    Seal, KH
    Lorvick, J
    Kral, AH
    Ciccarone, DH
    Moore, LD
    Lo, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) : 211 - 214
  • [8] Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach - The case study of Canada
    Fischer, B
    Haydon, E
    Rehm, J
    Krajden, M
    Reimer, J
    [J]. JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2004, 81 (03): : 428 - 447
  • [9] Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin:: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study
    Fried, MW
    Shiffman, ML
    Reddy, RK
    Smith, C
    Marino, G
    Goncales, F
    Haeussinger, D
    Diago, M
    Carosi, G
    Zarski, JP
    Hoffman, J
    Yu, J
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A55 - A55
  • [10] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    Manns, MP
    McHutchison, JG
    Gordon, SC
    Rustgi, VK
    Shiffman, M
    Reindollar, R
    Goodman, ZD
    Koury, K
    Ling, MH
    Albrecht, JK
    [J]. LANCET, 2001, 358 (9286) : 958 - 965